112 related articles for article (PubMed ID: 6606686)
1. Reduction of the immunosuppressive action of chemotherapeutics in patients with mammary carcinoma by Azimexon.
Kreienberg R; Boerner D; Melchert F; Lemmel EM
J Immunopharmacol; 1983; 5(1-2):49-64. PubMed ID: 6606686
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of intravenous azimexon therapy in human cancer.
Patt YZ; Hersh EM; Reuben J; Claghorn L; Mavligit G
J Biol Response Mod; 1986 Aug; 5(4):313-8. PubMed ID: 2874196
[TBL] [Abstract][Full Text] [Related]
3. Immunorestoration of anergic cancer patients by azimexon.
Goutner A; Nasrat F; Bonardelle D; Rameau G
Recent Results Cancer Res; 1980; 75():47-52. PubMed ID: 7232839
[TBL] [Abstract][Full Text] [Related]
4. The effect of BM 12.531 (azimexon) on natural killer cell activity in myeloma patients.
Peter HH; Dziuba-Traber H; Boerner D
Eur J Cancer Clin Oncol; 1984 Mar; 20(3):353-9. PubMed ID: 6368246
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of BM 12,531 (Prop. INN azimexon).
Bicker U
Recent Results Cancer Res; 1980; 75():147-52. PubMed ID: 7232826
[TBL] [Abstract][Full Text] [Related]
6. Treatment of metastatic breast cancer with AZQ: a phase II trial.
Martino S; Ratanatharathorn V; Samal BA; Singhakowinta A; Haas C
Cancer Invest; 1988; 6(3):289-91. PubMed ID: 3167612
[TBL] [Abstract][Full Text] [Related]
7. Effect of the immune modulators BM 12.531 (azimexone) and BM 41.332 on the subsets of T-lymphocytes in mice.
Olsson L; Bicker U
J Immunopharmacol; 1981-1982; 3(3-4):277-88. PubMed ID: 6215448
[TBL] [Abstract][Full Text] [Related]
8. Influence of the immunostimulating compound azimexone (2-[2-Cyanaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane) on the number of metastases in the Lewis lung carcinoma in mice.
Probst E; Maus W; Bicker U
Exp Pathol; 1981; 19(1):15-8. PubMed ID: 7262270
[No Abstract] [Full Text] [Related]
9. Aziridinylbenzoquinone (AZQ) in advanced breast cancer: a Cancer and Leukemia group B phase II trial.
Budman DR; Forastiere A; Perloff M; Perry M; Aisner J; Weinberg V; Wood W
Cancer Treat Rep; 1982 Oct; 66(10):1875-6. PubMed ID: 7127327
[No Abstract] [Full Text] [Related]
10. Three new agents for immunotherapy trials: azimexon, bestatin, and tuftsin.
Mathé G; Florentin I; Bruley-Rosset M; Goutner A; Serrou B
Recent Results Cancer Res; 1982; 80():331-3. PubMed ID: 6977171
[No Abstract] [Full Text] [Related]
11. Influence of the immunomodulating compound BM 12.531 (azimexone) on radioresistance and granulopoietic colony forming units in mice.
Gassel WD; Laukel H; Braun R; Werner T; Bicker U
Exp Pathol; 1981; 20(2):105-7. PubMed ID: 7327218
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation by the new synthetic compound BM 12.531, 2-[2-cyanaziridinyl-(1)]-[2-carbamoylaziridinyl-(1)]-propane (azimexone).
Luckenbach GA; Cortez-Campeao D; Modolell ML; Munder PG; Bicker U
Exp Pathol; 1981; 19(1):37-48. PubMed ID: 7262272
[No Abstract] [Full Text] [Related]
13. Phase II trial of diaziquone in advanced upper aerodigestive cancer.
Creagan ET; Long HJ; Kvols LK; Edmonson JH; O'Fallon JR
Cancer Treat Rep; 1985 Jan; 69(1):141. PubMed ID: 3967258
[No Abstract] [Full Text] [Related]
14. Azimexone and cysteine hydrazide in the treatment of allergic encephalomyelitis.
Błaszczyk B; Giełdanowski J; Woźniak M; Dobryszycka W; Lemmel EM; Katkiewicz M; Viljanen M
Arch Immunol Ther Exp (Warsz); 1988; 36(3):217-27. PubMed ID: 3266915
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-linked cytotoxic agents of potential value for the treatment of breast cancer.
Leclercq G; Devleeschouwer N; Legros N; Heuson JC
Eur J Cancer (1965); 1980; Suppl 1():287-93. PubMed ID: 7318866
[No Abstract] [Full Text] [Related]
16. High dose AZQ in renal cancer. A Southwest Oncology Group phase II study.
Stephens RL; Kirby R; Crawford ED; Bukowski R; Rivkin SE; O'Bryan RM
Invest New Drugs; 1986; 4(1):57-9. PubMed ID: 3700042
[TBL] [Abstract][Full Text] [Related]
17. Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by 2-[-2-cyanaziridinyl-(1)-]-2-[-2-carbamoylaziridinyl-(1)]-propane BM 12 531.
Bicker U; Hebold G; Ziegler AE; Maus W
Exp Pathol (Jena); 1978; 15(1):49-62. PubMed ID: 346364
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression after cholecystectomy.
Salo M; Eskola J
Acta Anaesthesiol Scand; 1977; 21(6):509-16. PubMed ID: 305179
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulating effects of BM 12.531 in animals and tolerance in man.
Bicker U
Cancer Treat Rep; 1978 Nov; 62(11):1987-96. PubMed ID: 728913
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical evaluation of AZQ in metastatic breast cancer.
Yap HY; Bedikian AY; Schell FC; Blumenschein GR; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):31-3. PubMed ID: 6837505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
